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Carﬁlzomib resistance due to ABCB1/MDR1 overexpression is
overcome by nelﬁnavir and lopinavir in multiple myeloma
A Besse1, SC Stolze2, L Rasche3, N Weinhold3, GJ Morgan3, M Kraus1, J Bader1, HS Overkleeft2, L Besse1 and C Driessen1
Proteasome inhibitor (PI) carﬁlzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple
myeloma (MM) frontline therapy and relapsed settings. Most MM patients ultimately experience PI-refractory disease, an unmet
medical need with poorly understood biology and dismal outcome. Pharmacologic targeting of ABCB1 improved patient outcomes,
including MM, but suffered from adverse drug effects and insufﬁcient plasma concentrations. Proteomics analysis identiﬁed ABCB1
overexpression as the most signiﬁcant change in CFZ-resistant MM cells. We addressed the functional role of ABCB1 overexpression
in MM and observed signiﬁcantly upregulated ABCB1 in peripheral blood malignant plasma cells (PCs) vs untreated patients’ bone
marrow PC. ABCB1 overexpression reduces the proteasome-inhibiting activity of CFZ due to drug efﬂux, in contrast to BTZ. Likewise,
the cytotoxicity of established anti-MM drugs was signiﬁcantly reduced in ABCB1-expressing MM cells. In search for potential drugs
targeting ABCB1 in clinical trials, we identiﬁed the HIV protease inhibitors nelﬁnavir (NFV) and lopinavir (LPV) as potent functional
modulators of ABCB1-mediated drug export, most likely via modulation of mitochondria permeability transition pore. NFV and LPV
restored CFZ activity at therapeutically relevant drug levels and thus represent ready-to-use drugs to be tested in clinical trials to
target ABCB1 and to re-sensitize PC to established myeloma drugs, in particular CFZ.
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INTRODUCTION
Treatment regimens based on proteasome inhibitors (PIs) or
immunomodulatory drugs are the current backbone of multiple
myeloma (MM) therapy.1 Bortezomib (BTZ), the ﬁrst-in class PI is a
reversible, boronate-type inhibitor, whereas carﬁlzomib (CFZ), a
second-generation PI, is an irreversible epoxyketone-based PI. The
catalytic core of the proteasome contains three pairs of
proteolytically active subunits with distinct substrate speciﬁcities
(β1, β2 and β5; caspase-like, trypsin-like and chymotrypsin-like
activity, respectively), out of which the β5 activity is rate limiting.2
Similar to BTZ, CFZ by design targets the β5 proteasome activity,
albeit with a higher selectivity for the proteasome.2 Next-
generation PI of the peptide boronate-type (ixazomib and
delanzomib), the epoxyketone-type (oprozomib) and the β-
lactone type (marizomib) share the same primary target and are
in advanced development or already approved.3 CFZ has superior
clinical anti-MM activity at a lower rate of neurotoxicity, compared
with BTZ.4 After initial approval of CFZ for MM treatment in the
relapsed/refractory setting, its approval advanced to second line
therapy together with lenalidomide/dexamethasone and it is
increasingly incorporated into frontline MM treatments in clinical
trials.4,5
MM treatment is usually not curative and most MM patients
relapse after PI treatment or become PI refractory,6,7 a condition
with a very poor prognosis.8 The development of PI resistance
under repetitive or continuing selective pressure with CFZ-
containing regimens is an emerging clinical problem9 The biology
of MM advances from intramedullary-restricted disease to
extramedullary manifestations and ﬁnally to leukemia-like features
with increasing proportions of malignant plasma cells (PCs) in the
peripheral blood (PB). PB malignant PC represent the most
aggressive state of MM cells and their number predict prognosis,
with the worst outcome for overt PC leukemia (PCL).10–12
Proteasome inhibition-based MM therapy induces apoptosis
through the induction of excessive proteotoxic stress.13,14
Resistance of MM cells to PI involves concerted changes in cell
maturation and metabolism.15,16 However, PI resistance is not
universal across the different classes of proteasome inhibiting
drugs, 16,17 suggesting drug-speciﬁc features.16 The biology of CFZ
resistance in MM is poorly understood. CFZ-resistant MM cells
show strong upregulation of ABCB1/P-gp, in contrast to BTZ-
resistant MM.16,18,19
ABC (ATP-binding cassette) transporters, such as ABCB1 (multi-
drug resistance protein, MDR-1/P-glycoprotein and P-gp), ABCC1
(multidrug resistance-associated protein, MRP-1) and ABCG2
(breast cancer-related protein) mediate generic drug resistance
of cancer by modulation of the absorption, disposition and
elimination of xenobiotics and drugs.20,21 ABCB1/P-gp is expressed
on malignant PC in PB in MM22,23 and is induced by chemother-
apeutic agents, such as doxorubicin, in more than 50% of MM
patients.24,25 ABCB1 is the single most overexpressed protein
when genetically matched CFZ-sensitive or resistant MM cell lines
are compared by quantitative whole proteome proﬁling.16.
Verapamil (VPM) as P-gp-inhibiting drug signiﬁcantly improved
MM treatment response in drug-resistant MM patients in the
pre-PI era.26,27 Although CFZ is a bona ﬁde substrate for ABCB1,18
conﬂicting data exist for BTZ.28,29 The functional role of ABCB1
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overexpression for PI resistance of MM and its implications for the
use of, or choice between, different PI drugs are unknown.
The HIV protease inhibitor (HIV-PI) drugs nelﬁnavir (NFV) and
lopinavir (LPV) by design inhibit the HIV protease, a viral enzyme
that lacks close homologies in eukaryotes.30,31 NFV and LPV have
been implicated in targeting antineoplastic pathways in human
cancer cells in preclinical models,32 including AKT and the
unfolded protein response, and were tested as sensitizing drugs
in combination with radiation or chemotherapy in the clinic.33–35
Recently, the combination of oral NFV with standard dose BTZ/
dexamethasone resulted in an 65% overall response rate in
patients with heavily pretreated PI-refractory MM.36 HIV-PI have
been suggested to be substrates of MDR proteins37,38 but also to
be MDR inhibitors.39
We here dissect the functional role of ABCB1 overexpression in
CFZ-resistant MM and address the effect of ABCB1 on the
cytotoxicity of standard MM drugs in vitro. We further identify
NFV and LPV as off-the-shelve drugs able to decrease ABCB1
activity, to overcome CFZ resistance and to boost the activity of
established drugs against advanced MM.
MATERIALS AND METHODS
Gene expression proﬁling and processing of patients’ data
Expression data of CD138+ PC from patients treated with Total Therapy
regimens were processed as previously described.40 Detailed description of
the Total Therapy regimens used is provided in Supplementary Table S1.
Brieﬂy, we used the Affymetrix U133 2.0 plus array custom (chip deﬁnition
ﬁle) (v19) mapping to Entrez genes (http://brainarray.mhri.med.umich.edu/
Brainarray/Database/CustomCDF/) as chip deﬁnition ﬁle. Expression data
were normalized using GC-RMA. We excluded genes with log2 expression
o3.5 in at least 95% of samples. Conﬁning our analysis to autosomal
genes expression data of 10,062 genes was available.
Cell lines
The ARH77 PCL cell line and the AMO-1 MM cell line were obtained from
commercial sources (American Type Culture Collection, Wesel, Germany
and Deutsche Sammlung von Mikroorganismen und Zellkulturen,
Braunschweig, Germany, respectively). Cells were maintained and adapted
to BTZ (AMO-BTZ and ARH77-BTZ) and CFZ (AMO-CFZ and ARH77-CFZ) as
previously described.16,41
Activity-based probes
Activity of proteasome subunits after PI treatment was assessed using the
recently developed set of subunit-selective activity-based probes that
differentially visualize individual activities of β1, β2 and β5 subunits of the
constitutive and immunoproteasome.42
Flow cytometry
Flow cytometric assessment of ABCB1 activity was performed using
Mitotracker green FM (ThermoFisher Scientiﬁc, Waltham, MA, USA), a well-
described substrate of ABCB1(43,44) and MVB003(45) (a gift from Professor
Overkleeft), an epoxyketone-based pan-reactive probe was used as ABCB1
substrate. Detailed and further description is provided in Supplementary
Methods.
Figure 1. Expression of ABC-type transporters in cell lines and patients’ primary cells. (a) RNA expression of ABCB1, ABCC2 and ABCG2
transporter in AMO-1, AMO-BTZ and AMO-CFZ cell lines. (b) Expression of ABCB1, ABCC2 and ABCG2 transporter in ARH77, ARH-BTZ and ARH-
CFZ cell lines. (c) Western blot validation of the overexpression of ABCB1 transporter in AMO-1 and ARH77 cell lines sensitive to PIs and their
resistant counterparts. (d) Expression of ABCB1, ABCC2 and ABCG2 in primary patient’s sample: MMs, sensitive to CFZ; MMr, resistant to CFZ
treatment. (e) Expression of ABCB1 and ABCG2 transporters in primary BTZ (BTZ-R) (n= 33) and CFZ (CFZ-R) (n= 29) resistant, newly diagnosed
(NDMM) (n= 1309) myeloma patients and in circulating PB–PC (n= 44). Signiﬁcant values o0.05 are marked with an asterisk (*).
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CRISPR/Cas9 knockout of ABCB1
The two-vector CRISPR/Cas9 system was introduced into AMO-CFZ cells by
lentiviral infection as described previously.46,47 Details are speciﬁed in
Supplementary Methods.
Statistical evaluation
Statistical evaluation was performed in GraphPad Prism v.5 (GraphPad
Software, La Jolla, CA, USA). For signiﬁcance level two-tailed unpaired t-test
was used, values Po0.05 were considered as statistically signiﬁcant. If not
indicated otherwise, results show one representative of at least three
independent experiments.
RESULTS
ABCB1 is consistently overexpressed in CFZ-resistant myeloma cell
lines
Expression of the three major subfamilies of ABC-type transporters
(ABCB1, ABCC2 and ABCG2) was assessed in AMO-1 and ARH77
cell lines, comparing the parental (PI-sensitive) cell lines (IC50 4.8–
6.3 nM) with their CFZ- or BTZ-resistant derivatives (AMO-BTZ,
AMO-CFZ, IC50 67–1342 nM) (Supplementary Table S2).
16,41 Expres-
sion of ABCB1 mRNA was selectively upregulated in CFZ-resistant
cells (Figures 1a and b), in contrast to BTZ-resistant cells, and
concordant with protein expression (Figure 1c). Consistent with
this, upregulation of ABCB1, but also ABCG2, was observed in a set
of paired MM samples isolated from a MM patient initially
responding to CFZ-based therapy and later progressing to PCL
under such therapy (baseline sample taken before initiating CFZ-
based therapy, second sample obtained during consecutive
disease progression of the same patient under CFZ/dexametha-
sone therapy (Figure 1d)). Gene expression analysis before therapy
from a patients cohort enrolled in ‘Total Therapy’ revealed that
ABCB1 was signiﬁcantly increased in CD138+ circulating PB–PC of
44 newly diagnosed patients with primary PCL, compared with
CD138+ bone marrow PC from 617 treatment-naive patients
(Figure 1e). Further, we did not observe a difference in ABCB1
expression between bone marrow PC from BTZ-refractory or CFZ-
refractory patients and non-refractory newly diagnosed patients.
ABCG2 expression was signiﬁcantly lower in PB–PC, compared
with bone marrow PC from treatment-naïve or BTZ-refractory
patients. We conclude that ABCB1 upregulation is a selective
feature of circulating malignant PC from MM patients, which is
associated with CFZ resistance in vitro.16
Proteasome-inhibiting activity of CFZ, but not BTZ, is decreased in
CFZ-resistant MM cells
We next addressed whether ABCB1 overexpression in CFZ-
resistant MM cells may lead to decreased cytotoxic activity due
to impaired intracellular proteasome inhibition. We visualized
proteasome activity of BTZ/CFZ-treated AMO-1, AMO-CFZ and
AMO-BTZ cells using proteasome selective activity-based chemical
probes, and at the same time assessed cell viability (Figures 2a
and b). With BTZ treatment, we observed dose-dependent
inhibition of β1 proteasome activity of very similar efﬁcacy in all
three cell types, as expected. BTZ likewise resulted in near-
complete β5 inhibition in AMO-1 and AMO-CFZ, whereas
β5 inhibition was less effective in AMO-BTZ, consistent with the
β5 active-site mutation present in these cells.16 CFZ treatment led
to very similar dose-dependent inhibition of β5 activity in AMO-1
and AMO-BTZ, and at high concentrations also β2 activity, as
expected. However, in AMO-CFZ, CFZ up to 100 nM lacked a
detectable inhibitory effect on intracellular β5 or β2 proteasome
activity. This corresponded to differential cytotoxic sensitivity of
AMO-CFZ and AMO-BTZ against their respective selecting drugs
(BTZ or CFZ): AMO-CFZ had an ~ 10-fold higher IC50 for CFZ than
for BTZ treatment and vice versa, and AMO-BTZ showed a 20-fold
higher IC50 for BTZ, compared with CFZ (Figures 2a and b, and
Supplementary Table S2).
To directly address the functional role of ABCB1 for CFZ
resistance, we eliminated ABCB1 protein in AMO-CFZ cells by
CRISPR/Cas9 (for example, clone 7) (Figure 3a). We observed an
inverse correlation between the levels of ABCB1 and myeloma cell
sensitivity to CFZ (Figure 3b, Supplementary Table S3). Subtotal
elimination of ABCB1 resulted in an approximately eightfold
decrease of the IC50 for CFZ. Together, these data demonstrate
that ABCB1-mediated export of CFZ limits CFZ-induced cytotoxi-
city in CFZ-resistant MM. Overexpressed ABCB1 is therefore a
therapeutic target for CFZ-resistant myeloma.
Figure 2. Comparison of dose–response of AMO-1 (sensitive) vs AMO-BTZ and AMO-CFZ (resistant) cells treated with PIs (BTZ and CFZ).
(a) Residual activity of proteasome subunits visualized by activity-based probe labeling in intact cells after 1 h pulse treatment with indicated PIs.
(b) Cell viability was measured after 48 hours of continuous treatment. Corresponding IC50 values are presented in Supplementary Table S2.
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ABCB1 overexpression interferes with activity of approved
myeloma drugs
To dissect the role of ABCB1 overexpression for the activity of
standard myeloma drugs we compared the cytotoxic effects of
such drugs on AMO-CFZ cells with (clone #1) or without such
ABCB1 expression (clone 7) (Figure 3c and Supplementary Table
S4). To score for good versus poor ABCB1-substrate myeloma
drugs, we calculated the ratio of IC50 values between the ABCB1-
containing and the ABCB1-deﬁcient clone for each of the
myeloma drug. For the known ABCB1 substrate daunorubicin,
this ratio was 4.8, whereas it was 1.6 for cyclophosphamide,
suggesting that cyclophosphamide is almost ABCB1 independent.
Interestingly, the epoxyketone-type proteasome inhibiting drugs,
(oprozomib and CFZ) scored even higher than daunorubicin in
this comparison (ratio of 6.7 and 7.8, respectively). Likewise,
panobinostat and delanzomib were considerably strong ABCB1
substrates, almost comparable to daunorubicin, with ratios of 4.4
and 3.7, respectively, whereas BTZ, lenalidomide and ixazomib
showed moderately low degrees of ABCB1 interaction with scores
around 2.6, 2.6 and 2, respectively, and marizomib (score of 1.6)
showed the weakest interaction with ABCB1. The data demon-
strate that cytotoxicity of the epoxyketones CFZ and oprozomib is
very sensitive to ABCB1 overexpression, whereas anti-MM activity
of marizomib is almost independent from level of ABCB1.
NFV and LPV strongly decrease ABCB1 activity
P-gp inhibition can functionally be assessed by measuring the
intracellular accumulation of ﬂuorescent dyes like Mitotracker
Green FM, which is exported from the cytoplasm by functional P-
gp.18 To exclude a possible interference of the dye with
Figure 3. Impact of ABCB1 knockdown on the sensitivity of AMO-1 cells. (a) Western blot evaluation of the ABCB1 depletion in AMO-CFZ
clones obtained by CRISPR/Cas9 genome editing tool. (b) Dose–response of AMO-CFZ clones with depleted ABCB1 to CFZ. Corresponding
IC50 values are presented in Supplementary Table S3. (c) Dose–response of selected AMO-CFZ clones 1 and 7 to CFZ and convectional drugs
used in the treatment of MM. (d) Dose–response of AMO-CFZ clones 1 and 7 to approved PI or those in clinical development. Corresponding
IC50 values are presented in Supplementary Table S4.
Overcoming MDR1-mediated carﬁlzomib resistance in MM
A Besse et al
394
Leukemia (2018) 391 – 401
mitochondria, a modiﬁed epoxyketone-based PI tagged with
ﬂuorescent probe, MVB003, was used. Culture of AMO-CFZ in the
presence of Mitotracker Green FM or MVB003 resulted in only a
weak ﬂuorescence signal from intracellular dye, consistent with
overexpression of ABCB1 and ABCB1-mediated export of the dye.
Addition of VPM or reserpine (RSP) in the micromolar range led to
a sizable, dose-dependent increase in cellular ﬂuorescence in
AMO-CFZ, as expected, consistent with the inhibition of P-gp
mediated export by the drugs (Figures 4a and b). A very similar
effect was observed when cells were co-incubated with the HIV-PI
NFV and LPV (Figures 4a and b), suggesting that NFV and LPV
likewise modulate P-gp in AMO-CFZ. NFV and LPV functionally
decreased P-gp activity already at drug concentrations between 5
and 10 μM already after 1 h incubation, matching the serum NFV/
LPV concentrations achieved in patients (Figure 4a and
Supplementary Figure S1).48
P-gp inhibition increases activity of CFZ in CFZ-resistant myeloma
We used activity-based probe to demonstrate that P-gp-inhibiting
drugs re-establish the intracellular proteasome-inhibiting activity
of CFZ in CFZ-resistant MM cells. AMO-CFZ and ARH-77-CFZ cells
showed adequate reduction in intracellular proteasome activity
upon pulse treatment with BTZ (25 nM, 1 h) compared with
untreated cells or NFV/LPV controls and proteasome activity was
not affected by co-treatment with VPM, RSP, NFV or LPV (10 μM) in
this setting. Proteasome activity was not affected when AMO-CFZ
and ARH-77-CFZ were treated with CFZ (50 nM, 1 h), consistent
with the results above. Strikingly, treatment with CFZ and the
MDR-1 inhibitors VPM, RSP, NFV or LPV (10 μM) restored the full
proteasome-inhibiting activity of CFZ (Figure 5a). We next
addressed whether such increase in intracellular proteasome
inhibition by co-administration of ABCB1-inhibiting drugs would
also functionally translate into increased intracellular accumula-
tion of proteasome substrate protein upon BTZ/ CFZ challenge.
AMO-CFZ were equipped with stable expression of GFP-modiﬁed
ubiquitin (UbG67V-GFP), which is incorporated in the poly-ubiquitin
chain to identify and quantify proteasome substrate proteins, so
that an increase in ﬂuorescence signiﬁes the intracellular
accumulation of proteasome substrate proteins.49 In untreated
AMO-CFZ_Ub-GFP cells or respective cells treated with NFV or LPV
alone, no signiﬁcant ﬂuorescence signal was detected, indicating
undisturbed proteasomal proteolysis. Treatment with 25 nM BTZ
resulted in signiﬁcant ﬂuorescence and thus functionally relevant
proteasome inhibition. This was further increased in the presence
of VPM, RSP, NFV or LPV. CFZ treatment (50 nM 1 h pulse) alone did
not result in an Ub-GFP-ﬂuorescence signal, whereas its combina-
tion with VPM, RSP, NFV or LPV again re-established functional
proteasome inhibition. Interestingly, of the clinically available
drugs, the synergistic effect of NFV and LPV with CFZ was
considerably stronger than VPM at the same concentration
(Figure 5b). Taken together, the data demonstrate that CFZ is a
strong substrate for ABCB1 and that MDR-blocking drugs can be
used to re-establish the proteasome-inhibiting activity of BTZ/CFZ
in CFZ-resistant MM cells. They further identify NFV and LPV as
Figure 4. Functional inhibition of ABCB1 by VPM, RSP, NFV and LPV evaluated by Mitotracker Green FM and MVB003 efﬂux. (a) Dose–response
inhibition of ABCB1 evaluated by Mitotracker Green FM (MTG) efﬂux after 12 h of treatment with indicated concentrations of compounds.
(b) Inhibition of ABCB1 after 12 h of treatment with 10 μM concentration of VPM, RSP, NFV and LPV evaluated by MTG and MVB003 efﬂux.
Signiﬁcant values o0.05 are marked with an asterisk (*).
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established drugs that mediate this effect at low micromolar
concentrations.
Mapping the ABCB1-modulating portion of NFV and mechanism
of P-gp inhibition by NFV and LPV
HIV-PI by design inhibit the HIV protease, which lacks close human
homologues. To map the ABCB1-inhibiting activity of NFV to a
functional region of the drug molecule, we synthesized two
analogues of NFV: SC451, a non-functional derivative where the
predicted target interaction site is occupied by an acyl group, and
compared its ABCB1-inhibiting activity to SC441, a structural
analog of NFV (Supplementary Figure S2). Although SC441
completely retained the CFZ-sensitizing activity of the NFV parent
drug, SC451 was inactive (Figure 6a and Supplementary Table S5).
This maps the ABCB1-inhibiting activity of NFV to the region of
SC451 occupied by the acyl group.
To reveal the underlying mechanism of ABCB1 modulation by
NFV and LPV, we performed PgP-Glo assay, which serves to
elucidate whether NFV and LPV are direct ABCB1 inhibitors or
substrates. NFV and LPV were conﬁrmed to be neither direct
inhibitors, nor strong ABCB1 substrates, similar to VPM (Figure 6b).
Therefore, we focused on the modulation of mitochondrial
function as an indirect mechanism of functional ABCB1 inhibition.
Indeed, NFV was shown to modulate mitochondria the activity of
the mitochondrial permeability transition pore (mPTP),50 and NFV
and LPV induce reactive oxygen species formation, which likely
mirrors a modulation of mitochondrila activity.51,52 Decylubiqui-
none, a known mPTP inhibitor antagonizes reactive oxygen
species production and likewise counteracted ABCB1 inhibition
induced by NFV or LPV (Figures 6c and d). On contrary, mPTP
facilitators (H2O2 or PK11195)
53 induced dose-dependent inhibi-
tion of ABCB1 function, leading to increased CFZ-mediated
cytotoxicity in AMO-CFZ (Figures 6e and f, Supplementary
Figure S3 and Supplementary Table S8). Thus, the data support
that mPTP function is activated by NFV and LPV, which in turn is
directly linked to ABCB1 inhibition.
As the mechanism of action of NFV to overcome PI resistance
likely involves additional mechanisms besides ABCB1 inhibition, we
aimed to establish the speciﬁc contribution of the ABCB1-mediated
vs ABCB1-independent role of NFV or LPV against MM. In the
presence of functional ABCB1, LPV or NFV treatment resulted in a
20–40-fold decrease of IC50 for CFZ. In the absence of ABCB1, LPV
and NFV retained sizable CFZ-sensitizing activity, but the decrease in
the IC50 was only 13–15-fold. A very similar pattern was also
observed for VPM and RSP co-treatment (16–60-fold and 11–13-fold,
respectively) (Figure 6g and Supplementary Tables S6A and B). This
is consistent with a functionally important role of ABCB1-mediated
export of CFZ in AMO-CFZ cells, which is reduced by NFV or LPV. It
further demonstrates that LPV and NFV target additional molecules
that substantially contribute to drug resistance.
NFV or LPV have superior PI-sensitizing activity in combination
with epoxyketone-type PIs
To address to what extent NFV or LPV likewise sensitizes myeloma
cells to next-generation PIs, we established the IC50 for the
approved proteasome inhibiting drugs or drug candidates: BTZ,
ixazomib, delanzomib (peptide boronate-based), CFZ, oprozomib,
the immunoproteasome-selective PR957 (epoxyketone) and the
β-lactone marizomib, in the presence/absence of NFV or LPV by
viability assays. The highest PI-sensitizing effect of NFV/LPV
(10–120-fold, Supplementary Table S7) was observed when
ABCB1-overexpressing cells (AMO-CFZ) were treated with the
strong ABCB1 substrates, such as the epoxyketone-type of
inhibitors CFZ or oprozomib (Figure 7). In cells with low ABCB1
expression (AMO-BTZ), NFV and LPV likewise increased the
sensitivity of PI-resistant cells for epoxyketone-type PI, although
the effect was considerably weaker compared with ABCB1-
overexpressing cells (AMO-CFZ). An exception here was marizo-
mib, which showed strong drug-sensitizing effect by NFV/LPV in
AMO-1 cells without features of adaptive resistance. These data
characterize LPV and NFV as powerful drugs to increase PI
sensitivity of MM cells towards the entire spectrum of proteasome
Figure 5. Impact of VPM, RSP NFV and LPV on the CFZ entrance into the AMO-CFZ cells. (a) Residual activity of proteasome subunits
visualized by activity-based probe labeling after 12 h pre-treatment with indicated compounds and subsequent 1 h treatment with 50 nM CFZ.
(b) AMO-CFZ stably expressing Ub-GFP co-treated for 12 h with 10 μM concentration of indicated compounds in combination with 50 nM CFZ.
Signiﬁcant values o0.05 are marked with an asterisk (*).
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inhibitory drugs or drug candidates. LPV and NFV are especially
effective in the CFZ-resistant setting and/or in combination
with CFZ.
DISCUSSION
We demonstrate that ABCB1 is overexpressed on circulating PB
malignant PC in newly diagnosed PCL patients, and that ABCB1
overexpression results in CFZ resistance via ABCB1-mediated
export of CFZ. However, we did not observe increase of ABCB1
expression in PC of CFZ-refractory patients. It has been previously
shown that PC loose P-gp function when they home to the bone
marrow and re-activate it again while leaving the marrow.23
Further, it has been shown that malignant MM cell population of
patients relapsing under PI treatment consist of multiple
subclones with different maturation stages within each subclone,
Figure 6. Evaluation of the speciﬁcity of NFV and LPV in the modulation of ABCB1 function and importance of ABCB1 in the CFZ resistance.
(a) Dose–response of AMO-CFZ resistant cells to CFZ and co-treatment with SC451 and SC441. Corresponding IC50 values are presented in
Supplementary Table S5. (b) Activity of ABCB1 evaluated by PgP-Glo assay. (c) Rescue experiment of ROS induction in AMO-CFZ after
treatment with mPTP inhibitor (decylubiqinone), NFV, LPV and combination evaluated by H2DCFDA staining. (d) Rescue experiment of
functional inhibition of ABCB1 in AMO-CFZ evaluated by MVB003 efﬂux after treatment with mPTP inhibitor (decylubiqinone), NFV, LPV and
combination. (e) Functional inhibition of ABCB1 in AMO-CFZ evaluated by MVB003 efﬂux after 30 min treatment with increasing
concentration of H2O2. (f) Functional decrease of ABCB1 function in AMO-CFZ evaluated by MVB003 efﬂux after 12 h treatment with
increasing concentration of PK11195, mPTP facilitator. (g) Dose–response of AMO-CFZ_ABCB1 high (1) and low (7) with or without 10 μM NFV
and 10 μM LPV co-treatment. Corresponding IC50 values are presented in Supplementary Table S6. Signiﬁcant values o0.05 are marked with
an asterisk (*).
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Figure 7. Sensitivity proﬁle of ABCB1 inhibitors co-treatment with PIs used in the clinic or in clinical development in AMO-1, AMO-BTZ and
AMO-CFZ cell lines. Dose–response curves of PI co-treated with NFV (10 μM) and LPV (10 μM). Corresponding IC50 values are presented in
Supplementary Table S7.
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from CD138+,CD38+ to CD138− ,CD38− ,CD20+ MM cells;15
therefore, gene expression proﬁling analysis of CD138+ cells is
likely not representative of the whole PI-resistant population.
Nevertheless, we show here that circulating PC are de-novo
expressing ABCB1. ABCB1 expression is likely a feature that is
rather speciﬁc for B-cells and circulating PC. Its expression has
been shown to correlate with poor prognosis, treatment
resistance and aggressive disease.22,54–56 Relevance of ABCB1
expression in MM is supported by its strong, consistent and
selective upregulation in several CFZ-resistant cell lines, as well as
in a malignant PC patient sample that was analyzed before and
after acquisition of CFZ resistance. The in vitro model of CFZ-
adapted MM cells used here matches the currently known major
characteristics of PI-refractory MM, such as lack of proteasome
mutation and IRE1/XBP1-low stage.15,16 Overexpression of the
ABCB1 drug exporter has been observed in MM cells, including
CFZ-resistant MM,16 but its functional signiﬁcance was unclear.
ABCB1 overexpression is predicted to result in P-gp-mediated
drug export. We directly demonstrate that increased ABCB1 limits
the proteasome-inhibiting activity and clearance of poly-
ubiquitinated protein by CFZ in CFZ-resistant malignant PC
overexpressing ABCB1, which results in signiﬁcantly reduced
cytotoxicity.
Our data implicate ABCB1 as a therapeutic target and a
modulator of the efﬁcacy of MM drugs in relapsed and highly
advanced MM and particularly in the CFZ-exposed setting. The
current therapeutic trend to place CFZ earlier in the MM treatment
algorithm and to foresee prolonged CFZ treatment periods may
contribute to an increased emergence of ABCB1-overexpressing
MM clones in the future. ABCB1 overexpression affected the
cytotoxic activity of epoxyketone-type PIs signiﬁcantly stronger
than non-epoxyketone PIs. Other than toxicity issues, there is
currently little rationale to use a particular class of PIs vs another
class to achieve the best possible anti-MM activity in the clinic. Our
data show that epoxyketone-type PIs are less active in ABCB1-
overexpressing MM, suggesting that ABCB1-overexpressing
patients may rather beneﬁt from other classes of PIs, in particular
marizomib or ixazomib. We also show that in vitro adaptation to
BTZ results in ~ 10-fold higher sensitivity to CFZ than to BTZ,
whereas the opposite is true when MM cells adapt to CFZ. Given
that most patients included in the ENDEAVOR trial were BTZ-
pretreated (and a signiﬁcant number even BTZ refractory), but
almost no patients were CFZ-pretreated, BTZ-pretreatment may
likewise have skewed the results towards favoring CFZ sensitivity
in the ENDEAVOR trial.4 This possibility may be taken into account
when interpreting the outcome of this head to head comparison.
Our results further suggest that ABCB1-overexpressing MM may
likewise have a low sensitivity to other strong ABCB1 substrate
drugs used in MM therapy, such as panobinostat or daunorubicin,
but may be better targeted with ixazomib, cyclophosphamide or
marizomib, which lack signiﬁcant ABCB1 interaction. Of the
established MM drugs, we identiﬁed cyclophosphamide as the
one with the least sensitivity to ABCB1-mediated export. This
matches well with the striking activity observed when cyclopho-
sphamide was added to a pomalidomide-dexamethasone back-
bone in patients with heavily pretreated MM, of which 44% were
CFZ refractory.9 The low sensitivity of cyclophosphamide to
ABCB1-mediated export could have signiﬁcantly contributed to
the therapeutic activity of cyclophosphamide in this setting in
heavily pretreated MM patients.
We here identify NFV and LPV, two approved HIV-PI, as potent
drugs preventing ABCB1-mediated export of CFZ by MM cells. NFV
and LPV overcome CFZ resistance at low micromolar concentra-
tions. Appropriate plasma levels of NFV (~10–15 μM) have been
consistently reached and tolerated well in a recent phase I trial,
where we tested escalating doses of NFV in combination with full
dose PI therapy in patients with advanced hematologic malig-
nancies, including PI-refractory MM.57 A respective national phase
II trial in BTZ-refractory MM achieved an 65% overall response rate
in heavily pretreated patients with PI-refractory MM, an unprece-
dented response rate in this category of patients achieved with
registered drugs.36 Swissmedic has granted orphan drug status to
NFV for MM treatment.
Previous attempts to establish P-gp inhibiting drugs as
chemotherapy sensitizers in MM have failed due to undesirable
pharmacokinetic interactions of the drugs used, their inability to
achieve sufﬁciently high plasma concentrations and the lack of a
diagnostic setup to safely identify patients with P-gp over-
expressing MM.58 NFV and LPV are off-the-shelf drugs that
overcome these limitations and may be tested in clinical trials.
The use of P-gp-sensitive intracellular dyes in conjunction with
ﬂow cytometry allows functional testing of patient MM cells for
P-gp activity in a broadly applicable fashion. This may allow
establishing a valid biomarker for MM patients that are likely to
beneﬁt from P-gp targeting drugs, like NFV or LPV. NFV and LPV
act synergistically with all known and future PI against MM in vitro
(Figure 7). In addition, they decrease ABCB1-mediated drug efﬂux
that limits the activity of non-PI MM drugs such as lenalidomide,
daunorubicine or panobinostat (Figure 3). Thus, NFV and LPV have
a very broad drug-sensitizing potential for MM therapy.
The molecular target of NFV in MM is still unknown. High doses
of NFV have been suggested to directly inhibit proteasome
function, but we have previously shown that NFV and LPV do not
impair proteasome activity at drug concentrations o40 μM and
likewise, NFV at drug-sensitizing concentrations of 10 μM did
neither affect proteasome subunit activity nor the accumulation of
polyubiquitinated proteasome substrate protein in our results
(Figure 5). We have also previously shown that NFV activates
unfolded protein response in PI-sensitive and PI-resistant cells,
which results in increased BTZ-sensitivity in vitro and is associated
with BTZ-sensitivity in the clinic.59 Here we further show that NFV
and LPV inhibit the ABCB1 efﬂux by facilitating the mPTP activity,
consistent with previous reports suggesting that NFV modiﬁes
mitochondria function by mPTP modulation.50 Our data obtained
with/without genetic ablation of ABCB1 in ABCB1-overexpressing
AMO-CFZ cells provide further proof that NFV and LPV act at least
in part through P-gp inhibition, in particular in cells with ABCB1
overexpression. The synergy between CFZ and NVF/LPV is
substantially higher than that seen for BTZ. However, the 41
log difference in IC50 between AMO-CFZ lacking ABCB1 expression
and treated with CFZ in the presence or absence of NFV clearly
demonstrates that additional molecular targets mediate the PI-
sensitizing activity of NFV. It is likely to be that NFV and LPV block
the activity of additional multidrug resistance proteins in a similar
manner. This is supported by the substantially larger accumulation
of UbG67V-GFP-labeled proteasome substrate proteins in CFZ-
resistant cells co-treated with RSP, NFV or LPV, compared with
VPM at the same dose (Figure 5). Although VPM is a rather
selective inhibitor of P-gp, RSP has a wider substrate selectivity
that includes several other multidrug resistance proteins.60
However, NFV and LPV also signiﬁcantly increased the sensitivity
of BTZ-resistant cells (which do not express MDR-type proteins)
against marizomib (PI with the lowest interaction potential with
ABCB1) and BTZ, suggesting that NFV/LPV act through additional
cellular targets beyond MDR-type drug export proteins. Impor-
tantly, we were able to map this activity to a deﬁned region within
the NFV compound. This truncated version of NFV may now be
used as a point of departure to identify the additional molecular
target(s) and to generate novel lead compounds against MM by
medical chemistry approaches aiming at substantially lower IC50
values.
In summary, we here demonstrate the functional importance of
ABCB1 overexpression and P-gp-mediated export of therapeutic
drugs, including CFZ, in CFZ-resistant MM. We further identify NFV
and LPV as ready-to-use, approved drugs that modulate P-gp
function and overcome P-gp-mediated drug resistance in MM,
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presumably by an indirect mechanism that involves mPTP. NFV
and LPV substantially increase the activity of several myeloma
drugs in this setting at concentrations that are clinically tolerable
and achievable. Our results open immediate options to exploit
these activities in clinical trials in advanced MM.
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